Sandoz drugs Jubbonti and Wyost are approved for use in all indications covered by the Amgen products, Prolia and Xgeva. But no launch date is planned yet, due to ongoing patent litigation between the two companies.
Insulin prices have long been a pain point for diabetics. The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
While Covid-19 has had a significant impact on drug spending, IQVIA projects that its effect will moderate in coming years. IQVIA’s new report on U.S. medicines spending projects that immunology, oncology, and neurology will continue to drive the growth in drug spending.
The FDA has approved the first biosimilar that references the blockbuster Roche drug Lucentis. The Biogen and Samsung BioLogics joint venture that developed the biologic product have approval to treat three eye conditions that lead to vision loss.
Legislators threaten to ban settlements where branded companies "pay" generics makers to "delay" market entry, while drugmakers say the current framework balances competition and innovation. Who will prevail?
Johnson & Johnson is hoping that its blockbuster drug will be protected through its network with large healthcare systems when biosimilar competition arrives to U.S. shores.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Also, Minneapolis nurses with five hospitals go on strike and Hologic became the third company to develop a blood test for the Zika Virus that U.S. regulators have greelighted for emergency use.
It's clear that more biosimilars are close to completion and marketing than not; 12 are in preclinical development, whereas 23 are almost ready to be filed.